NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy. The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development
 
Status Suspended
Process HST
ID number 911

Project Team

Project lead Leanne Wakefield

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
28 June 2016 Suspended, NICE is considering an evaluation of drisapersen for treating Duchenne muscular dystrophy. The Institute has now been informed by the company that it has withdrawn its Marketing Authorisation for drisapersen in this indication, from the European Medicines Agency. Therefore, NICE has decided to suspend this evaluation on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development
28 June 2016 Draft scope documents

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance